Back

Interplay between guideline-directed medical therapy and QRS duration in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure registry

31 August 2026 (08:15 - 08:45)
Organised by: Logo
Congress Presentation Part of: Improving HFrEF therapy further Heart Failure with Reduced Ejection Fraction (HFrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Renzo Laborante

South General Hospital, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
The impact of late-onset reverse remodeling in heart failure with reduced ejection fraction
Doctor H. Ikesugi (Niigata, JP)
Abstract Slides Video
Presentation thumbnail
Cardiac reverse remodelling of left heart during vericiguat therapy for high-risk HFrEF
Professor A. Lee (Hong Kong, CN)
Abstract Slides Video
Presentation thumbnail
Impact of higher comorbidity burden on guideline-directed medical therapy in patients with heart failure with reduced ejection fraction
Mr J. Krabbe (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Clinical profile and implementation of guideline-directed medical therapy in specialised heart failure clinics: insights from a multicentre registry
Doctor C. Castro (Talca, CL)
Abstract Slides Video

Access the full session

Session thumbnail
Improving HFrEF therapy further

The Event

Event poster

ESC Congress 2026

31 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Structured optimization of QRS duration reduction post-Cardiac Resynchronization Therapy is feasible and shorter QRS duration is associated with better clinical outcome
4 April 2022
thumbnail
Congress Presentation
Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)
1 September 2025
thumbnail
Congress Presentation
Impact of QRS duration on drug titration and left ventricular recovery in new-onset heart failure with reduced ejection fraction
31 August 2025
thumbnail
Congress Presentation
Electrocardiographic predictors of response to sacubitril/valsartan therapy in patients with heart failure and reduced ejection fraction: a retrospective cohort study
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources